Skip to main content
x

IN8bio cuts costs on registrational delay

On the face of it IN8bio’s plan to go all in on its unmodified gamma-delta T-cell project INB-100, after promising early data at EHA in June, seems reasonable. But a closer look shows why the company needs the funds from a reprioritisation, announced yesterday, that will involve halving its workforce. IN8bio had hoped to go straight into a registrational study based on the phase 1 results, which came from an investigator-sponsored trial. But after meeting the FDA the company now says it will seek to add a control arm to the existing trial – presumably at the agency’s request. Meanwhile, enrolment into a 25-patient dose-expansion cohort is expected to complete in the first half of 2025. IN8bio’s August corporate presentation noted that the group could file an IND for a phase 2 randomised, controlled trial in the first half of 2025, and included a slide on the study’s design; this slide wasn’t included in the group’s September presentation. As well as cutting jobs, IN8bio is also deprioritising its glioblastoma candidates INB-200 and INB-400. The group’s stock was down 13% in premarket trading this morning.

 

In and out: IN8bio’s pipeline

ProjectDescriptionIndicationStatus
Still active
INB-100Unmodified allogeneic gamma-delta T cellsAMLPh1 investigator-sponsored trial; 25-pt expansion & control cohorts planned
INB-300Non-signalling Car-expressing gamma-delta T cellsTBDPreclinical
INB-500Gamma-delta iPSC T cellsTBDPreclinical
Deprioritised
INB-400Modified allogeneic/autologous gamma-delta T cellsGlioblastomaPh1/2; follow-up data due 2025
INB-200Modified autologous gamma-delta T cellsGlioblastomaPh1; follow-up data due Q4 2024

Source: company presentation.

This story has been updated to reflect what was included in IN8bio's September presentation.

Tags

Companies